Visit our new beta site!

Wyeth's comeback kid: Robert Essner guides the pharma giant back from the fen-phen brink.(PHARMACEUTICALS)

From: Chief Executive (U.S.)  |  Date: 10/1/2005  |  Author: Hawthorne, Fran

Robert Essner, chief executive officer of drug company Wyeth, doesn't want to talk about the F-word.

[ILLUSTRATION OMITTED]

That's F as in fen-phen, the diet drug combination that caused severe and sometimes fatal heart and lung malfunctions in tens of thousands of people in the 1990s. Wyeth marketed the dangerous "fen" half of it--the drugs fenfluramine and dexfenfluramine, sold under the brand names Pondimin and Redux. To date, Wyeth has set aside more than $21 billion to ...

Browse by alphabet: